Blood Thinners Xarelto, Pradaxa Among Drugs Companies Pay Most to Promote

In the last five months of 2013, drug makers spent nearly $20 million to promote medications hospitals and healthcare providers. Among the top 20 drugs listed by Business Insider that companies pay the most to promote are Xarelto and Pradaxa, two blood thinners alleged to cause complications in lawsuits.

If you took Xarelto or Pradaxa and suffered severe bleeding complications, call Attorney Group for a free consultation. We can answer your questions, and if you have a case, we can connect you with an affiliated blood thinner lawsuit attorney who can file a lawsuit on your behalf and help you seek the compensation to which you may be entitled.

Most Promoted Drugs Include Xarelto, Pradaxablood thinners

Severe side effects have been reported after patients used blood thinners Xarelto and Pradaxa, and lawsuits have been filed claiming the drug makers failed to adequately warn the medical community and consumers of the potential risks associated with the drugs. Plaintiffs have alleged the drug makers failed to disclose risks associated with use of Xarelto and Pradaxa, include severe bleeding complications.

According to the article by Business Insider, among the drugs companies pay the most to promote, Xarelto and Pradaxa are sixth and thirteenth, respectively. The article suggests competition to be the cause of drug companies’ promotional spending. Nine products out of the twenty listed had a competitor treating the same condition also ranked within the top 20. Anti-clotting Drugs Eliquis and Brilinta were also listed, ranked at second and third respectively.

Contact Attorney Group to Learn More

If you or a loved one has taken Xarelto or Pradaxa and suffered internal bleeding or another severe complication, call Attorney Group. We can provide you with a consultation at no out-of-pocket cost to you, and if you have a case, we can connect you with an affiliated attorney who can file a lawsuit on your behalf and help you seek the compensation to which you may be entitled.

Comments